Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

novartis_side_building

Novartis’ Xolair scores European approval to treat chronic rhinosinusitis with nasal polyps

August 6, 2020
Sales and Marketing Novartis, Xolair, rhinosinusitis

Novartis has snapped up approval from the European Commission for its anti-immunoglobulin E (IgE) antibody therapy Xolair (omalizumab) for the …

News
kymriah

Novartis’ CAR T therapy Kymriah nails main goal in follicular lymphoma

August 4, 2020
Manufacturing and Production, Research and Development CAR-T therapy, Cancer, Kymriah, Novartis, car t therapy

Novartis is celebrating the success of its one-time CAR T therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory (r/r) …

News
novartis_outside_1

Novartis’ Cosentyx gets European go-ahead in paediatric plaque psoriasis

August 3, 2020
Sales and Marketing Cosentyx, Europe, Novartis, pharma, psoriasis

Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) has chalked up approval from the European Commission (EC) for the treatment of patients …

News
novartis_outside_1

Novartis’ Piqray combo becomes first Europe-approved therapy for PIK3CA-mutated advanced breast cancer

July 29, 2020
Research and Development, Sales and Marketing Europe, Novartis, Piqray, breast cancer, pharma

The European Commission (EC) has awarded its approval for Novartis’ Piqray (alpelisib) to be made available in combination with fulvestrant …

News

Novartis to provide ‘no-profit’ generics to low income countries to help combat COVID-19

July 16, 2020
Business Services COVID-19, Novartis, coronavirus, hydroxychloroquine

The Sandoz division of Novartis will not make a profit on the 15 generics it is making available to developing …

News

Novartis agrees to pay $347 million to settle bribery allegations

June 26, 2020
Medical Communications Greece, Novartis, bribery

Novartis and its former eye care unit Alcon have agreed to pay a combined $347 million to resolve allegations that …

News

NICE knocks back Novartis’ Mayzent in secondary progressive multiple sclerosis over data gaps

June 25, 2020
Sales and Marketing Mayzent, NHS, NICE, Novartis

Novartis’ Mayzent (siponimod) has been unsuccessful in securing a recommendation from NICE for use on the NHS for the treatment …

News
novartis_outside_1

Novartis’ Cosentyx hits primary goal in Phase 3 non-radiographic axial spondyloarthritis study

June 4, 2020
Research and Development Cosentyx, Novartis, axial spondyloarthritis

New Phase 3 data has been released on the efficacy of Novartis’ interleukin (IL)-17A inhibitor Cosentyx (secukinumab), showing that the …

News

Novartis releases results of MS drug trials weeks ahead of FDA verdict

May 28, 2020
Business Services MS, Novartis

Novartis has revealed clinical trial data from testing its anti-CD20 leukameia drug Arzerra (ofatumumab) in patients with multiple sclerosis (MS). …

News

FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14

May 7, 2020
Sales and Marketing Incyte, Novartis, Tabrecta, pharma

The FDA has awarded marketing authorisation to Novartis for the Oral MET inhibitor Tabrecta (capmatinib) for the first-line treatment of metastatic non-small …

News
novartis_outside_1

EU approval for Novartis’ Cosentyx in active non-radiographic axial spondyloarthritis

April 29, 2020
Research and Development, Sales and Marketing Cosentyx, EU, Novartis, axial spondyloarthritis, pharma

Novartis has revealed that the European Commission has moved to approve Cosentyx (secukinumab) for the treatment of active non-radiographic axial …

News

Novartis’ Jakavi Phase 3 trial is first of its kind to hit main goal in steroid-refractory acute graft-versus-host disease

April 23, 2020
Research and Development Jakavi, Novartis, pharrma

Novartis has revealed impactful new Phase 3 data for its therapy Jakavi (ruxolitinib) in the treatment of patients with steroid-refractory …

News
novartis_outside_1

Five-year data supports early treatment with Novartis’ Mayzent in secondary progressive multiple sclerosis

April 21, 2020
Manufacturing and Production, Research and Development Mayzent, Novartis, pharma

Novartis has pulled back the curtain on five-year data from an extension trial for its sphingosine 1-phosphate receptor modulator Mayzent …

News
alimera_sciences_logo

Steven T Gill returns to Alimera as VP, Thought Leader Engagement

April 3, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alimera Sciences, Novartis, pharma

Ophthalmology specialist Alimera Sciences has announced that Steven T Gill is to return to the company in the newly created …

Appointment
00_novartis

FDA places no penalties on Novartis after Zolgensma data manipulation investigation

April 2, 2020
Business Services FDA, Novartis, regulators

The FDA has concluded its investigation into Novartis and its data manipulation of the gene therapy Zolgensma, and has decided …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025